Autopsy report · NCT00276159

Study of Immune Response Modifier in the Treatment of Hematologic Malignancies

“Drug was not available.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 10 months before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 1 year 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Masonic Cancer Center, University of Minnesota

Sponsor type

University, hospital or other

Conditions

Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Non-Hodgkin's Lymphoma; Hodgkin's Lymphoma; Multiple Myeloma; Chronic Lymphocytic Leukemia

Interventions

852A

Participants

6

Sites

1

Countries

United States

Trials that died the same way

• Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
  “Drug was no longer available” (88% match in meaning)
• Role of Oxytocin in Telling and Detecting Lies
  “Drug not available” (83% match in meaning)
• Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome
  “Drug unavailable” (80% match in meaning)
• TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)
  “Drug no longer available” (79% match in meaning)
• An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NSCLC
  “The study drug, Famitinib, was not marketed and the drug was not available.” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.